[1]王万胜,王 晨,沈 健,等.复合125I粒子植入技术联合TACE治疗肝癌合并门静脉癌栓[J].介入放射学杂志,2021,30(07):680-686.
　WANG Wansheng,WANG Chen,SHEN Jian,et al.Complex 125I seed implantation combined with transcatheter arterial chemoembolization for hepatocellular carcinoma complicated by portal vein tumor thrombus[J].journal interventional radiology,2021,30(07):680-686.
点击复制

复合125I粒子植入技术联合TACE治疗肝癌合并门静脉癌栓()

PDF下载中关闭

分享到：

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
30
期数:
2021年07
页码:
680-686
栏目:
非血管介入
出版日期:
2021-07-29

文章信息/Info

Title:
Complex 125I seed implantation combined with transcatheter arterial chemoembolization for hepatocellular carcinoma complicated by portal vein tumor thrombus
作者:
王万胜;  王 晨;  沈 健;  任葆胜;  印 于;  杨 俊;  唐浩桓;  黄 鹏;  朱晓黎; 倪才方
Author(s):
WANG Wansheng;  WANG Chen;  SHEN Jian;  REN Baosheng;  YIN Yu;  YANG Jun;  TANG Haohuan;  HUANG Peng;  ZHU Xiaoli;  NI Caifang.
Department of Interventional Radiology， First Affiliated Hospital of Soochow University， Suzhou， Jiangsu Province 215006， China
关键词:
【关键词】 肝细胞癌;  门静脉癌栓;  125I粒子螺旋系统;  复合125I粒子植入技术; 血管内近程放疗;  经动脉化疗栓塞术
文献标志码:
A
摘要:
【摘要】 目的 评估复合125I粒子植入技术（125I粒子螺旋系统序贯肿瘤同侧分支癌栓粒子植入术）联合TACE治疗肝细胞癌（HCC）合并程氏Ⅲ型门静脉癌栓（PVTT）的安全性及有效性。方法 对24例HCC合并Ⅲ型PVTT患者行门静脉主干内125I粒子螺旋系统植入术，随后同期行TACE治疗；7～10 d后继行肿瘤同侧分支癌栓内125I粒子植入术。每6～8周行CT增强随访，并按需行再次TACE治疗。统计分析患者并发症、治疗反应率及总生存期。 结果 所有患者均未发生3级以上严重并发症。门静脉主干癌栓（MPVTT）的客观反应率（ORR）与疾病控制率（DCR）分别为54.2%及87.5%；肝内病变的ORR及DCR分别为29.2%及37.5%。患者中位生存期为（9.5±1.4）（95%CI，6.7～12.3）个月。结论 复合125I粒子植入技术联合TACE治疗HCC合并Ⅲ型PVTT是安全可行的，该模式有望进一步改善此类患者预后。

参考文献/References:

［1］ Minagawa M， Makuuchi M. Treatment of hepatocellular carcinoma accompanied by portal vein tumor thrombus［J］. World J Gastroe- nterol， 2006， 12：7561- 7567.
［2］ Llovet JM， Bustamante J， Castells A， et al. Natural history of untreated nonsurgical hepatocellular carcinoma： rationale for the design and evaluation of therapeutic trials［J］. Hepatology， 1999； 29：62- 67.
［3］ Villa E， Moles A， Ferretti I， et al. Natural history of inoperable hepatocellular carcinoma： estrogen receptors’ status in the tumor is the strongest prognostic factor for survival［J］. Hepatology， 2000， 32：233- 238.
［4］ Geschwind JF， Kudo M， Marrero JA， et al. TACE treatment in patients with sorafenib- treated unresectable hepatocellular carcinoma in clinical practice： final analysis of GIDEON［J］. Radiology， 2016， 279：630- 640.
［5］ Cheng AL， Kang YK， Chen Z， et al. Efficacy and safety of sorafenib in patients in the Asia- Pacific region with advanced hepatocellular carcinoma： a phase Ⅲ　randomised， double- blind， placebo- controlled trial［J］. Lancet Oncol， 2009， 10：25- 34.
［6］ Llovet JM， Ricci S， Mazzaferro V， et al. Sorafenib in advanced hepatocellular carcinoma［J］. N Engl J Med， 2008， 359：378- 390.
［7］ Kudo M， Finn RS， Qin S， et al. Lenvatinib versus sorafenib in first- line treatment of patients with unresectable hepatocellular carcinoma： a randomised phase 3 non- inferiority trial［J］. Lancet， 2018， 391：1163- 1173.
［8］ Finn RS， Ryoo BY， Merle P， et al. Results of KEYNOTE- 240： phase 3 study of pembrolizumab（Pembro） vs best supportive care （BSC） for second line therapy in advanced hepatocellular carci-noma（HCC）［J］. J Clin Oncol， 2020， 38：193- 202.
［9］ Yau T， Park JW， Finn RS， et al. LBA38- PR- CheckMate 459： a randomized， multi- center phase Ⅲ studyof nivolumab（NIVO） vs sorafenib（SOR） as first- line（1L） treatment in patients with advanced hepatocellular carcinoma（aHCC）［J］. Ann Oncol， 2019， 30：v874-v 875.
［10］ Zhang FJ， Li CX， Jiao DC， et al. CT guided 125 iodine seed implantation for portal vein tumor thrombus in primary hepato-cellular carcinoma［J］. Chin Med J（Engl）， 2008， 121：2410- 2414.
［11］ Huang M， Lin Q， Wang H， et al. Survival benefit of chemoem- bolization plus iodine 125 seed implantation in unresectable hepatitis B- related hepatocellular carcinoma with PVTT： a retros- pective matched cohort study［J］. Eur Radiol， 2016， 26：3428- 3436.
［12］ Zhang ZH， Zhang W， Gu JY， et al. Treatment of hepatocellular carcinoma with tumor thrombus with the use of iodine- 125 seed strand implantation and transarterial chemoembolization： a propen- sity- score analysis［J］. J Vasc Interv Radiol， 2018， 29：1085- 1093.
［13］ Wang W， Shen J， Wang C， et al. Safety and feasibility of helical I- 125 seed implants combined with transcatheter arterial Chem- oembolization in hepatocellular carcinomas with main portal vein tumor thrombus［J］. Cardiovasc Intervent Radiol， 2019， 42：1420- 1428.
［14］ Yang M， Fang Z， Yan Z， et al. Transarterial chemoembolisation （TACE） combined with endovascular implantation of an iodine- 125 seed strand for the treatment of hepatocellular carcinoma with portal vein tumour thrombosis versus TACE alone： a two- arm， randomised clinical trial［J］. J Cancer Res Clin Oncol， 2014， 140：211- 219.
［15］ Luo J， Yan Z， Liu Q， et al. Endovascular placement of iodine- 125 seed strand and stent combined with chemoembolization for treatment of hepatocellular carcinoma with tumor thrombus in main portal vein［J］. J Vasc Interv Radiol， 2011，22：479- 489.
［16］ Luo JJ， Zhang ZH， Liu QX， et al. Endovascular brachytherapy combined with stent placement and TACE for treatment of HCC with main portal vein tumor thrombus［J］. Hepatol Int， 2016， 10：185- 195.
［17］ Lu J， Guo JH， Zhu HD， et al. Safety and efficacy of irradiation stent placement for malignant portal vein thrombus combined with transarterial chemoembolization for hepatocellular carcinoma： a single- center experience［J］. J Vasc Interv Radiol， 2017， 28：786- 794.
［18］ 胡鸿涛， 黎海亮， 郭晨阳， 等. 125I粒子植入联合动脉化学栓塞治疗原发性肝癌合并门静脉癌栓［J］. 中华放射学杂志， 2012， 46：552- 556.
［19］ 吴林霖，颜志平，张 雯，等. 经动脉灌注化疗联合125I粒子条治疗原发性肝癌合并门脉癌栓的疗效分析［J］. 介入放射学杂志， 2015， 24：776- 780.
［20］ 杨 亮，顾玉明，徐 浩，等. 门静脉125I粒子条联合肝动脉化疗栓塞治疗原发性肝癌合并门静脉癌栓的疗效［J］. 中华肝胆外科杂志， 2019， 25：885- 889.
［21］ Wang C， Wang W， Shen J， et al. Feasibility of helical I- 125 seed implant in the portal vein［J］. Cardiovasc Intervent Radiol， 2019； 42：121- 129.
［22］ Shuqun C， Mengchao W， Han C， et al. Tumor thrombus types influence the prognosis of hepatocellular carcinoma with the tumor thrombi in the portal vein［J］. Hepatogastroenterology， 2007， 54：499- 502.
［23］ 中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范（2019年版）［J］. 临床肝胆病杂志， 2020， 36：277- 292.
［24］ Chung JW， Park JH， Han JK， et al. Hepatocellular carcinoma and portal vein invasion： results of treatment with transcatheter oily chemoembolization［J］. AJR Am J Roentgenol， 1995， 165：315- 321.
［25］ Lencioni R， Llovet JM. Modified RECIST（mRECIST） assessment for hepatocellular carcinoma［J］. Semin Liver Dis， 2010， 30：52- 60.
［26］ Zhang YF， Guo RP， Zou RH， et al. Efficacy and safety of preoperative chemoembolization for resectable hepatocellular carcinoma with portal vein invasion： a prospective comparative study［J］. Eur Radiol， 2016， 26：2078- 2088.
［27］ Kothary N， Weintraub JL， Susman J， et al. Transarterial chemo- embolization for primary hepatocellular carcinoma in patients at high risk［J］. J Vasc Interv Radiol， 2007， 18：1517- 1526.
［28］ Yu TZ， Zhang W， Liu QX， et al. Endovascular brachytherapy combined with portal vein stenting and transarterial chemoembo-lization improves overall survival of hepatocellular carcinoma patients with main portal vein tumor thrombus［J］. Oncotarget， 2017， 8：12108- 12119.

相似文献/References:

[1]姚雪松,李 槐.不可手术切除的肝细胞癌的疗效评价标准——改良ＲＥＣＩＳＴ标准更可靠[J].介入放射学杂志,2012,(03):177.
　. Ｔｈｅｒａｐｅｕｔｉｃ ｅｖａｌｕａｔｉｏｎ ｃｒｉｔｅｒｉｏｎ ｏｆ ｉｎｏｐｅｒａｂｌｅ ｈｅｐａｔｏｃｅｌｌｕｌａｒ ｃａｒｃｉｎｏｍａｓ： ｍｏｄｉｆｉｅｄ ＲＥＣＩＳＴ ａｓ ａ ｍｏｒｅ ｒｅｌｉａｂｌｅ ｓｔａｎｄａｒｄ[J].journal interventional radiology,2012,(07):177.
[2].关于召开“全国肝癌介入治疗研讨会”的通知[J].介入放射学杂志,1995,(04):200.
[3]梁茂全,苏洪英. 肝癌化疗栓塞前后甲胎蛋白变化模式的临床意义[J].介入放射学杂志,2012,(04):333.
　.Ｔｈｅ ｔｒａｎｓｆｏｒｍａｔｉｏｎ ｐａｔｔｅｒｎ ｏｆ ｓｅｒｕｍ аｆｅｔｏｐｒｏｔｅｉｎ ａｆｔｅｒ ｔｒａｎｓｃａｔｈｅｔｅｒ ａｒｔｅｒｉａｌ ｃｈｅｍｏｅｍｂｏｌｉｚａｔｉｏｎ ｉｎ ｐａｔｉｅｎｔｓ ｗｉｔｈ ｈｅｐａｔｏｃｅｌｌｕｌａｒ ｃａｒｃｉｎｏｍａ： ｉｔｓ ｃｌｉｎｉｃａｌ ｓｉｇｎｉｆｉｃａｎｃｅ [J].journal interventional radiology,2012,(07):333.
[4]孙 磊,施海彬,刘 圣,等.肝细胞癌肝动脉门静脉分流形成的相关因素分析[J].介入放射学杂志,2012,(03):206.
　,,et al.Ｔｈｅ ｆａｃｔｏｒｓ ｒｅｌａｔｅｄ ｔｏ ｔｈｅ ｆｏｒｍａｔｉｏｎ ｏｆ ａｒｔｅｒｉｏｐｏｒｔａｌ ｓｈｕｎｔｉｎｇ ｉｎ ｐａｔｉｅｎｔｓ ｗｉｔｈ ｈｅｐａｔｏｃｅｌｌｕｌａｒ ｃａｒｃｉｎｏｍａｓ [J].journal interventional radiology,2012,(07):206.
[5]沈海洋,刘瑞宝,刘 岩,等. 肝右叶前、后段原发性肝癌TACE后VEGF及CD34的表达水平 ；[J].介入放射学杂志,2012,(06):469.
　SHEN Hai- yang,LIU Rui- bao,LIU Yan,et al. The expression levels of vascular endothelial growth factor and CD34 in residual cancerous tissues of primary hepatocellular carcinoma located at anterior and posterior segments of right lobe liver after TACE[J].journal interventional radiology,2012,(07):469.
[6]李晓峰,钱国军,张 磊,等. 微波高功率条件下消融原发性肝癌的初步研究[J].介入放射学杂志,2011,(12):974.
　LI Xiao-feng,QIAN Guo-jun,ZHANG Lei,et al.Microwave ablation with high output power for the treatment of hepatocellular carcinoma: a preliminary study[J].journal interventional radiology,2011,(07):974.
[7]张　　　磊,陆骊工,李　　　勇,等.门静脉支架联合肝动脉化疗栓塞治疗肝癌伴门静脉癌栓的临床研究[J].介入放射学杂志,2011,(12):968.
　ZHANG Lei,LU Li-gong,LI Yong,et al.Portal vein stent placement combined with TACE for the treatment of hepatocellular carcinoma associated with tumor thrombus in portal vein[J].journal interventional radiology,2011,(07):968.
[8]彭辽河,胡晓燕,李 杰,等. 18F-FDG PET/CT显像在肝细胞癌TACE术后残留或复发病灶检出中的应用价值[J].介入放射学杂志,2012,(08):636.
　PENG Liao- he,HU Xiao- yan,LI Jie,et al. Clinical application of 18F- FDG PET/CT imaging in detecting residual lesions or recurrence foci of hepatocellular carcinoma after TACE treatment[J].journal interventional radiology,2012,(07):636.
[9]陆小华,朱小庆,茅国新.肝细胞癌相关单核苷酸多态性的研究进展[J].介入放射学杂志,2013,(06):520.
　LU Xiao? hua,ZHU Xiao? qing,MAO Guo? xin.. Hepatocellular carcinoma?蛳 related single nucleotide polymorphisms： recent advances in research[J].journal interventional radiology,2013,(07):520.
[10]李海伟,刘 静,李 森.125I粒子植入与伽玛刀治疗门脉癌栓的疗效对比[J].介入放射学杂志,2014,(08):702.
　LI Hai wei,LIU Jing,LI Sen..125Iodine seed implantation and gamma knife for the treatment of portal vein tumor thrombosis in hepatocellular carcinoma： comparison of therapeutic efficacy[J].journal interventional radiology,2014,(07):702.
[11]黄文薮,蔡明岳,曾昭吝,等.TACE联合125I放射性粒子植入治疗肝细胞癌门静脉癌栓[J].介入放射学杂志,2015,(06):488.
　HUANG Wen- sou,CAI Ming- yue,ZENG Zhao- lin,et al.Transarterial chemoembolization combined with CT- guided 125I seed implantation for the treatment of hepatocellular carcinoma associated with portal vein tumor thrombus[J].journal interventional radiology,2015,(07):488.
[12]陈 嵩,吴志强,庄文权,等.经肝动脉栓塞术联合FOLFOX4方案持续动脉灌注化疗治疗肝细胞癌合并门静脉癌栓15例近期临床疗效评价[J].介入放射学杂志,2019,28(04):328.
　CHEN Song,WU Zhiqiang,ZHUANG Wenquan,et al.TAE combined with continuous hepatic artery infusion chemotherapy with FOLFOX4 scheme for HCC associated with PVTT： evaluation of its short- term efficacy in 15 patients[J].journal interventional radiology,2019,28(07):328.
[13]刘 琦,张 颖,张精文,等.HAIC联合靶向和免疫治疗晚期肝癌伴门脉主干癌栓的研究[J].介入放射学杂志,2024,33(07):738.
　LIU Qi,ZHANG Ying,ZHANG Jingwen,et al.HAIC combined with targeted therapy and immunotherapy for advanced liver cancer complicated by main portal vein tumor thrombus： a clinical study[J].journal interventional radiology,2024,33(07):738.

备注/Memo

备注/Memo:
（收稿日期：2020- 09- 04）
（本文编辑：俞瑞纲）
更新日期/Last Update: 2021-07-28